Clinical Trial Update: CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating an in vivo CAR-T therapy targeting CD19 and BAFF-R for relapsed/refractory B-cell acute lymphoblastic leukemia and malignant lymphoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Lymphoma

Drugs mentioned

• CD19/BAFF-R in vivo CAR-T cell therapy

Snippet

Sponsor: Qi deng | Conditions: Lymphoma, CAR T Cell Therapy | Phase 1 | Status: NOT_YET_RECRUITING